Business Wire

ADVA brings sub-microsecond synchronization to utility and broadcast networks

Share

ADVA (FSE: ADV) today announced that it has extended the capabilities of its compact Oscilloquartz PTP timing technology to enable power utility and broadcast networks to achieve sub-microsecond synchronization. Now electricity companies can harness the accuracy needed for smart power grids, and media enterprises can meet key timing challenges. The two upgraded solutions are the pluggable OSA 5401, the market’s smallest PTP grandmaster clock, and the highly versatile OSA 5405, an integrated PTP grandmaster with dual GNSS antenna and receiver. Both technologies have proved critical in the telecommunications industry, where they have been widely deployed across the globe. They offer outstanding precision and unrivaled design density. Thanks to unique spoofing and jamming detection capabilities, they also provide unbeatable availability.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191008005048/en/

The OSA 5401 and OSA 5405 now enable power utility and broadcast networks to achieve sub-microsecond synchronization (Photo: Business Wire)

The OSA 5401 and OSA 5405 now enable power utility and broadcast networks to achieve sub-microsecond synchronization (Photo: Business Wire)

“This upgrade is big news for utility and media network operators looking to harness the most advanced innovation in their field. With our OSA 5401 and 5405 bringing new levels of accuracy and resilience to their infrastructure, they can reap the benefits of emerging bandwidth-intensive, latency-sensitive applications,” said Nir Laufer, senior director, product line management, Oscilloquartz, ADVA. “These devices are feature rich and incredibly efficient. But as well as their versatility, what really sets them apart is their extremely small footprint and low power consumption. This is key to bringing packet time distribution to the edge of network. With our technology ensuring sub-microsecond synchronization, smart grids can perform flexible, real-time decision making, as well as monitoring and automated maintenance. And for media companies, the possibilities for high-quality, interactive broadcasting from any location are enormous.”

The OSA 5401 and OSA 5405 now comply with the latest PTP profiles for time, frequency and phase synchronization in both power utility and broadcast networks. These include the IEC/IEEE 61850-9-3 Power Utility Profile for precise time distribution and clock synchronization in electrical grids with an accuracy of 1μs, and SMPTE 2059 for synchronizing video and audio equipment over packet networks. By supporting NTP, both solutions also enable enterprises to run an on-premises NTP server for high levels of accuracy and uncompromised availability. What’s more, the OSA 5401 and OSA 5405 include advanced GNSS jamming and spoofing detection mechanisms, which are integrated in a centralized AI-based GNSS assurance toolkit.

Taking up zero real estate and using very little power, the OSA 5401 can be deployed in the most space-restrictive locations. Its capabilities include multi-constellation GNSS (GPS/GLONASS/BEIDOU) and accurate time and frequency recovery, even in challenging environments such as urban canyons. Available in both indoor and outdoor variants, the OSA 5405 radically simplifies and extends the reach of GNSS antenna installation by allowing operators to forget about archaic and expensive RF cables and instead use simple Ethernet over copper cables or optical fiber. With the OSA 5405, highly precise GNSS-sourced synchronization is supported by network-based SyncE and PTP backups for highly stable sub-microsecond timing accuracy.

“Our mission is to make precise, resilient and affordable timing available in every industry. Both our OSA 5401 and OSA 5405 have had a significant impact on communication service provider networks, supporting mass small cell rollout and the transition to 5G connectivity. Now we’re ready to bring accurate, reliable and cost-efficient PTP timing to the edge of power and broadcast networks,” commented Ulrich Kohn, director, technical marketing, ADVA. “One feature of these devices that will prove key to network operators in these industries is their unique spoofing and jamming detection capabilities. These work on two layers. Firstly, network elements identify disruption autonomously. Then, on top of that, a layer powered by AI analyzes information from multiple devices. Using machine learning, this delivers the highly sophisticated and extremely robust protection needed for machine type communication applications in energy grid protection and control.”

Further information can be found in these slides: https://adva.li/power-and-broadcast-slides.

A supporting solution brief is also available: https://adva.li/broadcast-solution-brief.


About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we're building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com.

About Oscilloquartz
Oscilloquartz is a pioneer in time and frequency synchronization. We design, manufacture and deploy end-to- end synchronization systems that ensure the delivery and assurance of highly precise timing information over next-generation packet and legacy networks. As an ADVA Optical Networking company, we're creating new opportunities for tomorrow's networks. For more information, please visit us at www.oscilloquartz.com.

Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com

Contact information

For ADVA press:
Gareth Spence
t +44 1904 699 358
public-relations@adva.com

For ADVA investors:
Stephan Rettenberger
t +49 89 890 665 854
investor-relations@adva.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Idriverplus Joins the “Automate with Velodyne” Ecosystem29.5.2020 20:31:00 CESTPress release

Velodyne Lidar, Inc. and Idriverplus today announced an expanded partnership and Idriverplus inclusion into the Automated with Velodyne integrator ecosystem, which helps companies grow their businesses while using Velodyne lidar technology. Through the program, Velodyne will further collaborate with Idriverplus to support its continued innovation and promote Idriverplus autonomous vehicles, including street cleaners, passenger cars and logistics vehicles. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200529005589/en/ Velodyne Lidar, Inc. and Idriverplus announced an expanded partnership and Idriverplus inclusion into the Automated with Velodyne integrator ecosystem, which helps companies grow their businesses while using Velodyne lidar technology. (Photo: Velodyne Lidar) Recently, Velodyne signed a multi-year sales agreement with Idriverplus to provide Puck™ sensors for the mass production of autonomous vehicles. Idriverplu

Takeda Announces Compelling Data from the Phase 2 Trial of Pevonedistat Plus Azacitidine in Patients with Higher-Risk MDS29.5.2020 14:00:00 CESTPress release

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced the results of the Phase 2 Pevonedistat-2001 trial will be presented during oral sessions at the virtual 56thAmerican Society of Clinical Oncology (ASCO) Annual Meeting and the virtual 25thEuropean Hematology Association (EHA) Annual Meeting. The study evaluated pevonedistat plus azacitidine versus azacitidine alone in patients with rare leukemias, including higher-risk myelodysplastic syndromes (HR-MDS). These results show that the combination of pevonedistat and azacitidine is a highly active, promising therapeutic approach and suggest benefit in the HR-MDS subgroup across multiple clinically meaningful endpoints, including overall survival (OS), event-free survival (EFS), complete remission (CR) and transfusion independence, with a safety profile similar to azacitidine alone. The Pevonedistat-2001 trial was designed as a proof-of-concept study in patients with HR-MDS, higher-risk chronic myelomonocytic leukemi

Takeda Receives Positive CHMP Opinion for Pre-Filled Syringe Presentation of TAKHZYRO ® (lanadelumab) for Use as a Preventive Treatment for Hereditary Angioedema Attacks29.5.2020 14:00:00 CESTPress release

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion on a Type II Variation regulatory application and recommended the approval of a pre-filled syringe presentation of TAKHZYRO® (lanadelumab). TAKHZYRO is a subcutaneous injectable prescription medication approved in Europe for routine prevention of recurrent attacks of hereditary angioedema (HAE) in patients aged 12 years and older. HAE is a rare genetic disorder that results in recurrent attacks of oedema – swelling – in various parts of the body, including the abdomen, face, feet, genitals, hands and throat.1,2,3 “Our goal is to continuously innovate in all areas of HAE management,” said Isabel Kalofonos, Global Product Strategy Lead, HAE, Takeda. “This positive opinion marks another important step forward as we aim to enhance the experience of treatment administration for peo

Interim Data from the Open Label Phase 2 OPTIC Study of Iclusig ® (ponatinib) for Chronic Phase-CML Presented at the ASCO and EHA Virtual Meetings29.5.2020 14:00:00 CESTPress release

Incyte (Nasdaq:INCY) today announced that data from the interim analysis of the Phase 2 OPTIC (Optimizing Ponatinib Treatment In CML) trial, which was sponsored by Takeda and co-funded by Incyte, will be presented during an oral session at the upcoming 2020 American Society of Clinical Oncology Virtual Meeting (ASCO20; May 29 – May 31) (Abstract #7502)1; and at the virtual 25th Congress of the European Hematology Association (EHA25; June 11 – 14) (Abstract #S172)2. The OPTIC trial is an ongoing randomized, open-label study prospectively evaluating response-based dosing regimens of Iclusig® (ponatinib) over a range of three starting doses (45 mg, 30 mg, 15 mg) with the aim of optimizing its efficacy and safety in patients with chronic-phase chronic myeloid leukemia (CP-CML), who are resistant or intolerant to prior tyrosine kinase inhibitor (TKI) therapy. With a median follow up of approximately 21 months, data from the interim analysis of the OPTIC trial show that the optimal benefit-r

Takeda to Present Data from the ICLUSIG ® (ponatinib) Clinical Trial Program that Could Prove Practice-Changing for the Treatment of Chronic-Phase CML29.5.2020 14:00:00 CESTPress release

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced that interim analysis data from the Phase 2 OPTIC (Optimizing Ponatinib Treatment In CML) trial will be presented during an oral session at the virtual 56thAmerican Society of Clinical Oncology (ASCO) Annual Meeting and the 25thEuropean Hematology Association (EHA) Annual Meeting. The OPTIC trial is an ongoing, randomized, open-label study prospectively evaluating response-based dosing regimens of ICLUSIG® (ponatinib) over a range of three starting doses (45-, 30-, or 15-mg) with the aim of optimizing its efficacy and safety in patients with chronic-phase chronic myeloid leukemia (CP-CML) who are resistant or intolerant to prior tyrosine kinase inhibitor (TKI) therapy. With a median follow-up of approximately 21 months, data from the interim analysis of OPTIC show that the optimal benefit-risk profile for ICLUSIG in patients with CP-CML is achieved with a daily starting dose of 45-mg and, upon achieving ≤1% BCR-A

LetsGetChecked Debuts FDA EUA-Authorized At-Home Coronavirus (COVID-19) Sure-track Test29.5.2020 13:57:00 CESTPress release

LetsGetChecked, the leading direct-to-consumer at-home health testing and insights company, announces today the authorization of the new Coronavirus (COVID-19) Sure-track Test for at-home consumer use by the U.S. Food and Drug Administration under an EUA. The new test is authorized to serve at-risk individuals with a proprietary at-home PCR nasal swab test that delivers accurate and definitive results within 24 hours. Offering an end-to-end model, LetsGetChecked’s new Sure-track Test introduces the most complete FDA EUA-authorized Coronavirus at-home testing solution. The at-home Coronavirus (COVID-19) test incorporates a nasal swab and PCR lab analysis, offering convenient and secure results in 24 hours. Unlike serology tests that detect the presence of antibodies, the at-home COVID-19 test determines the presence or absence of SARS-CoV-2 viral RNA. LetsGetChecked’s Sure-track Test is the only FDA EUA-authorized at-home Coronavirus (COVID-19) test that owns all aspects of the testing